Early Improvements of Individual Symptoms With Antipsychotics Predict Subsequent Treatment Response of Neuropsychiatric Symptoms in Alzheimer’s Disease

Nagata, Tomoyuki; Shinagawa, Shunichiro; Yoshida, Kazunari; Noda, Yoshihiro; Shigeta, Masahiro; Mimura, Masaru; Nakajima, Shinichiro

doi:10.4088/jcp.19m12961

Cited by 6 publications

(1 citation statement)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Atypical antipsychotics have shown favorable therapeutic responses in apathetic AD patients [68][69][70][71]. A re-analysis of the CATIE-AD Study [72], in 421 patients with DSM-IV AD, demonstrated that reduction of NPI apathy score at week 2 was significantly associated with subsequent treatment response with atypical antipsychotics at week 8 (p < 0.05). The general use of antipsychotics is not advised in these patients due to serious adverse effects [73].…”

Section: Atypical Antipsychoticsmentioning

confidence: 99%

A Systematic Review of Pharmacological Interventions for Apathy in Aging Neurocognitive Disorders

et al. 2023

View full text Add to dashboard Cite

Objective: Apathy, a frequent neuropsychiatric symptom in aging neurocognitive disorders, has been associated with cognitive decline and functional disability. Therefore, timely provision of pharmacological interventions for apathy is greatly needed. Design: A systematical literature review of existing studies was conducted up to 30 May 2023 in several databases (PubMed, PsychInfo, Cochrane, Google Scholar, etc.) that included randomized controlled trials (RCTs) and meta-analyses assessing pharmacological treatments for apathy in aging neurocognitive disorders. The quality of the studies was appraised. Results: In patients with Alzheimer’s Disease (AD), donepezil, galantamine, rivastigmine, methylphenidate, and gingko biloba were proven efficacious for apathy, while rivastigmine, cognitive enhancer IRL752 and piribedil were found to be beneficial in patients with Parkinson’s Disease (PD) and agomelatine in patients with Frontotemporal Dementia (FD). The extensive proportion of RCTs in which apathy was used as a secondary outcome measure, along with the considerable methodological heterogeneity, did not allow the evaluation of group effects. Conclusions: Pharmacological interventions for apathy in aging neurocognitive disorders are complex and under-investigated. The continuation of systematic research efforts and the provision of individualized treatment for patients suffering from these disorders is vital.

show abstract